X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to explore novel approaches to improving therapeutic potency of cell and gene therapies by leveraging Xcellbio’s AVATAR™ incubator system for cell therapy research and development.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Cell and Gene therapy
Recipient: Xcell Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 11, 2024
Details:
ALVR105 (posoleucel) is a T-lymphocyte cell therapy which is under phase 3 clinical development for the treatment of adenovirus infections, BK virus infections & Epstein-Barr virus infection.
Lead Product(s): Posoleucel
Therapeutic Area: Infections and Infectious Diseases Product Name: ALVR105
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 22, 2023
Details:
The company intends to use the net proceeds to complete enrollment and achieve data readouts in all three of its ongoing Phase 3 trials of its lead multi-virus specific candidate, Viralym-M (posoleucel), an allogeneic, off-the-shelf multi-virus specific T cell therapy.
Lead Product(s): Posoleucel
Therapeutic Area: Infections and Infectious Diseases Product Name: Viralym-M
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $7.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 21, 2023
Details:
The proceeds will advance the company’s technology platforms, Life Edit gene editing, iPSCs, and RNA, cell, protein, vector engineering and BaseCamp®, to accelerate the design, manufacturing, and development of cell and gene therapies.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Undisclosed
Partner/Sponsor/Collaborator: AyurMaya Capital Management Fund
Deal Size: $401.0 million Upfront Cash: Undisclosed
Deal Type: Series D Financing May 24, 2023
Details:
Viralym-M (posoleucel) is a multi-virus specific T cell therapy (VST) targeting five viral pathogens ((BKV), (CMV), (AdV), (EBV), HHV-6). It is designed to play an important role in providing bridging immunity between conditioning and reconstitution of their immune system.
Lead Product(s): Posoleucel
Therapeutic Area: Infections and Infectious Diseases Product Name: Viralym-M
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2023
Details:
Viralym-M (posoleucel) is a multi-virus specific T cell therapy (VST) targeting five viral pathogens ((BKV), (CMV), (AdV), (EBV), HHV-6). It is designed to play an important role in providing bridging immunity between conditioning and reconstitution of their immune system.
Lead Product(s): Posoleucel
Therapeutic Area: Infections and Infectious Diseases Product Name: Viralym-M
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2023
Details:
Affini-T will leverage ElevateBio BaseCamp’s LentiPeak™ lentiviral vector technology platform and cell therapy production capabilities to advance its investigational oncogenic driver programs into clinical development.
Lead Product(s): TCR-engineered T Cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: Affini-T Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership November 15, 2022
Details:
The partnership with CIRM reflects the novelty of the iPSC platform and recognition of next-generation cell lines that address industry challenges and could potentially save time and costs for partners developing iPSC-derived therapeutic.
Lead Product(s): iPSC-based Therapeutic
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: California Institute for Regenerative Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership August 23, 2022
Details:
Peer-reviewed publication in Cell Stem Cell unveils a novel differentiation process from develop mature immune cells from induced pluripotent stem cells (iPSCs), a potentially disruptive advantage in the development of allogeneic iPSC-derived immunotherapies.
Lead Product(s): iPSC-derived Allogeneic Immune Therapies
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 04, 2022
Details:
AlloVir intends to use the net proceeds from the offering, to complete enrollment and achieve data readouts in all three of the Company’s ongoing Phase 3 trials of its lead multi-virus specific T-cell therapy candidate, posoleucel (Viralym-M).
Lead Product(s): Posoleucel
Therapeutic Area: Infections and Infectious Diseases Product Name: Viralym-M
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Kite Pharma
Deal Size: $126.6 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 27, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
